scholarly journals Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))

2018 ◽  
Author(s):  
Yasemin Küley-Bagheri ◽  
Karl-Anton Kreuzer ◽  
Ina Monsef ◽  
Michael Lübbert ◽  
Nicole Skoetz
Keyword(s):  
Retinoic Acid ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Promyelocytic Leukaemia ◽  
Promyelocytic Leukaemia ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Acute Myeloid

scholarly journals Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia

2019 ◽  
Vol 47 (2) ◽  
pp. 1064-1071 ◽  
Author(s):  
Yan Lin ◽  
Rongrong Lin ◽  
Guangquan Zhou ◽  
Yue Liu ◽  
Weimin Dong ◽  
...  
Keyword(s):  
Overall Survival ◽  
Retinoic Acid ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Median Overall Survival ◽  
Myeloproliferative Neoplasm ◽  
Primary Myelofibrosis ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Acute Myeloid

Primary myelofibrosis (PMF) is a type of cloned myeloproliferative neoplasm stemming from haematopoietic stem cells, and tends to transform to acute myeloid leukaemia (AML) in approximately 10–20% of cases over a 10-year period. The transformation into AML has a poor prognosis, with a median overall survival of only 2.6 months in patients receiving supportive treatment. To date, treatment of AML transformation remains poor. The case of a 58-year-old female patient with AML transformed from PMF, who was treated with decitabine combined with all-trans retinoic acid, is reported. The patient had complete remission and a 17-month overall survival from initial diagnosis of transformed AML, with tolerated haematologic toxicity during the treatment period.

Sign in / Sign up

Export Citation Format

Share Document